Biogen, Inc. has been on the hunt during the past few years for outside assets that can help diversify its largely neurology-focused portfolio, and CEO Chris Viehbacher has been adamant that the company should pursue opportunities in adjacent areas where it has experience, such as immunology and rare diseases. The acquisition of Human Immunology Biosciences, Inc. (HI-Bio) for $1.15bn up front announced on 22 May checks both therapeutic area boxes.
Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Lead Drug Felzartamab Is Pipeline-In-A-Product
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.
More from Deals
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
• By
After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.
• By
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
More from Business
• By
Private Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.
• By
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
• By
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.